OncoMatch/Clinical Trials/NCT07181161
Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer
Is NCT07181161 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments including AZD0516 and AZD9574 for metastatic prostate cancer.
Treatment: AZD0516 · AZD9574 — The main purpose of this study is to assess the safety and tolerability of AZD0516 as monotherapy and/or in combination with other anti-cancer agents for treatment of metastatic prostate cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Prostate Cancer
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: STEAP2 targeting modality
Previous treatment with a STEAP2 targeting modality
Cannot have received: chemotherapeutic agent that inhibits topoisomerase activity or metabolic enzymes
chemotherapeutic agent that inhibits topoisomerase activity or metabolic enzymes
Lab requirements
Blood counts
Adequate organ and marrow function in the absence of blood transfusion or growth factor support (within 21 days prior to the scheduled first dose of study intervention)
Kidney function
Adequate organ and marrow function in the absence of blood transfusion or growth factor support (within 21 days prior to the scheduled first dose of study intervention)
Liver function
Adequate organ and marrow function in the absence of blood transfusion or growth factor support (within 21 days prior to the scheduled first dose of study intervention)
Adequate organ and marrow function in the absence of blood transfusion or growth factor support (within 21 days prior to the scheduled first dose of study intervention)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Research Site · Fayetteville, Arkansas
- Research Site · Los Angeles, California
- Research Site · Boston, Massachusetts
- Research Site · Ann Arbor, Michigan
- Research Site · Detroit, Michigan
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07181161 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior STEAP2 targeting modality, chemotherapeutic agent that inhibits topoisomerase activity or metabolic enzymes disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 130 years or younger.
Is this trial open to female patients?
No. This trial enrolls male patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages